Evidence map›Paper›PMID 41027936›Full record

ArticleNature communications2025

Synthetic protein degradation circuits using programmable cleavage and ligation by Sortase A.

Hopen K Yang, Pragati K Muthukumar, Wilfred Chen

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hopen K Yang *Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.ORCID http://orcid.org/0009-0009-6218-2536
Pragati K Muthukumar *Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.ORCID http://orcid.org/0009-0003-4200-8422
Wilfred ChenDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA. wilfred@udel.edu.ORCID http://orcid.org/0000-0002-6386-6958

Funding

Chemistry-Biology Interface Predoctoral Training Grant 2024-2029T32GM133395 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine Leimkuhler Grimes · 2019 to 2026
$3.7M
National Science Foundation (NSF) 1817675National Science Foundation (NSF) 2013991NIGMS NIH HHS T32 GM133395
6 · The paper itself

Abstract

BioPROTACs are heterobifunctional proteins designed for targeted protein degradation (TPD). They are useful not only for probing protein functions but also offer a therapeutic avenue for modulating disease-related proteins. To extend the use of TPD beyond just protein attenuation, we introduce a synthetic framework for logic-gated, switchable TPD to achieve conditional control of protein content. By exploiting both the cleavage and ligation functionalities of Sortase A (SrtA), we present a new strategy utilizing SrtA as the control input to direct bioPROTAC activity for switchable TPD. Furthermore, by layering the SrtA input with protease gating, conditional degradation phenotypes can be readily adapted with minimal modifications to the design. This Logic-gated AdPROM deploying SrtA-mediated Element Recombination (LASER) platform allows us to expand the possible protein degradation outcomes in mammalian cells using Boolean logic operations depending on the input combinations. The flexibility to modulate the level of multiple native intracellular proteins can potentially lead to applications from therapy to diagnostics and biotechnology.

Indexed as

AminoacyltransferasesBacterial ProteinsCysteine EndopeptidasesProtein EngineeringProteolysisHEK293 CellsHumansAminoacyltransferasesBacterial ProteinsCysteine Endopeptidasessortase A

Identifiers

PMID41027936
PMCPMC12484588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.